| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 12.0% | 1.7% | 6.7% |
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| 6.7% | 27.4% | 16.1% | -15.9% | 43.4% | 14.7% |
Summers Value Fund LP delivered 6.7% net returns in 2025, bringing since-inception annualized returns to 12.0% versus 6.9% for the Russell 2000 Index. The fund maintains a concentrated healthcare-focused strategy targeting small-cap companies with limited institutional coverage and sell-side research. The investment approach centers on identifying special situations including spin-offs, management changes, asset sales, and business model pivots within the healthcare sector. Portfolio construction emphasizes fundamental value analysis with strict margin of safety requirements, seeking companies trading at discounts to intrinsic value using cash flow yield or asset value methodologies. The fund operates with no leverage or derivatives, focusing on companies with strong balance sheets and little debt. Risk management is achieved through position sizing based on risk profiles, with large positions representing 11-15% of portfolio for lowest-risk opportunities. The strategy has demonstrated strong downside protection with 37% down-market capture ratio versus Russell 2000, while maintaining 64% up-market participation. Historical performance includes one acquisition per year with premiums ranging from 17% to 207%.
Summers Value Fund invests in small-cap healthcare companies representing special situations with unrecognized long-term growth potential, using fundamental research to identify value in companies undergoing positive change while maintaining strict margin of safety requirements.
Fund maintains long-term investment horizon with focus on companies undergoing positive change where temporary challenges are within management's ability to rectify given sufficient time. Continues to seek special situations with unrecognized long-term growth potential in healthcare sector.
| Date | Letter | Tickers | Keywords | Pitches | Quick Takes |
|---|---|---|---|---|---|
| Jan 12 2026 | 2025 Q4 | CCSI, DPLO, ELMD, ENDP, NVO | concentrated, healthcare, long-term, small caps, special situations, value | - | Fund focuses exclusively on healthcare sector with concentrated portfolio of small-cap companies. Investment approach targets special situations within healthcare including spin-offs, asset sales, business model pivots, and new product launches. Portfolio includes pharmaceutical, medical device, biotechnology, and healthcare IT companies. Fund employs fundamental value-oriented approach with focus on margin of safety and intrinsic value calculations. Seeks companies trading at discounts to long-term intrinsic value using cash flow yield or asset value methodologies. Emphasizes downside protection relative to estimate of intrinsic value. Concentrated portfolio of small-cap companies with limited sell-side coverage and institutional ownership. Invests where most institutional managers cannot or will not participate, allowing for asymmetric return potential. 44% of Russell 2000 stocks have zero Wall Street coverage, creating mispriced opportunities. |
| Jan 12 2026 | 2025 Q4 | CCSI, DPLO, ELMD, ENDP, NVO | concentrated, healthcare, long-term, small caps, special situations, value | CCSI | Fund focuses exclusively on healthcare sector with concentrated portfolio of small-cap companies. Investment approach targets special situations within healthcare including spin-offs, asset sales, business model pivots, and new product launches. Portfolio includes pharmaceutical, medical device, biotechnology, and healthcare IT companies. Fund employs fundamental value-oriented approach with focus on margin of safety and intrinsic value calculations. Seeks companies trading at discounts to long-term intrinsic value using cash flow yield or asset value methodologies. Emphasizes downside protection relative to estimate of intrinsic value. Concentrated portfolio of small-cap companies with limited sell-side coverage and institutional ownership. Invests where most institutional managers cannot or will not participate, allowing for asymmetric return potential. 44% of Russell 2000 stocks have zero Wall Street coverage, creating mispriced opportunities. |
| Nov 8 2025 | 2025 Q3 | ADMA, DERM, LGND, QURE | biopharma, demographics, healthcare, innovation, regulation | - | The fund argues that healthcare, despite facing regulatory uncertainty, budget constraints, and political risk, now presents one of the most attractive investment environments in years. Investor outflows and sentiment deterioration have created mispricings, while fundamentals remain supported by innovation, demographics, and acquisition demand from large pharma. The manager is increasing exposure to biopharma and specialty healthcare names with strong product pipelines and cash-flow potential. |
| Sep 2 2025 | 2025 Q2 | DERM, INSP | downside protection, free cash flow, Mean reversion, valuation, value | DERM | The commentary highlights deep value opportunities created by investor pessimism and forced selling. Mean reversion and improving fundamentals are expected to drive returns as sentiment normalizes. Balance sheet strength and margin of safety remain central to capital protection. |
| Apr 30 2025 | 2025 Q1 | ADMA, CCSI | - | - | |
| Dec 31 2024 | 2024 Q4 | ELMD, INDV, MODV, PINC, UFPT, UTMD, ZIMV | - | - | |
| Feb 27 2024 | 2023 Q4 | INSP, LFCR, SPOK, UFPT, UTMD, VRTV, ZIMV | - | - | |
| Jan 31 2023 | 2022 Q4 | LFCR, UFPT, UTMD | - | - | |
| Dec 31 2021 | 2021 Q4 | MODV, NOTV, PLXP, UFPT, UTMD | - | - | |
| Dec 31 2020 | 2020 Q4 | BASI, ELMD, MODV | - | - |
| QUARTER | THEMES | TAGS |
|---|---|---|
| 2025 Q4 |
HealthcareHealthcare was the strongest relative contributor in the quarter with holdings increasing nearly +16% compared to benchmark returns of roughly +12%. Exact Sciences was acquired for a significant premium by Abbott Laboratories resulting in an +86% return, while other strong performers included Tarsus Pharmaceuticals, Glaukos following approval of a new product, Penumbra, and Repligen driven by strong earnings results. |
M&A Product Approval Earnings Biotech |
Small CapsSmall caps getting strong start in 2026 supported by easing monetary conditions and constructive fiscal backdrop. Small caps more sensitive to economic cyclicality which is overdue for expansion. Expected to grow at better pace than large caps in 2026 after long period of underperformance. |
Value Growth Cyclical Monetary Policy Fiscal Policy | |
ValueManager emphasizes investing in controlled companies trading at significant discounts to NAV, with European holding companies showing discounts of 30-68%. The strategy focuses on securities mispricing where real value exists, contrasting with overvalued technology stocks. |
Discounts NAV Mispricing Undervalued Controlled | |
| 2025 Q4 |
HealthcareHealthcare was the strongest relative contributor in the quarter with holdings increasing nearly +16% compared to benchmark returns of roughly +12%. Exact Sciences was acquired for a significant premium by Abbott Laboratories resulting in an +86% return, while other strong performers included Tarsus Pharmaceuticals, Glaukos following approval of a new product, Penumbra, and Repligen driven by strong earnings results. |
M&A Product Approval Earnings Biotech |
Small CapsSmall caps getting strong start in 2026 supported by easing monetary conditions and constructive fiscal backdrop. Small caps more sensitive to economic cyclicality which is overdue for expansion. Expected to grow at better pace than large caps in 2026 after long period of underperformance. |
Value Growth Cyclical Monetary Policy Fiscal Policy | |
ValueManager emphasizes investing in controlled companies trading at significant discounts to NAV, with European holding companies showing discounts of 30-68%. The strategy focuses on securities mispricing where real value exists, contrasting with overvalued technology stocks. |
Discounts NAV Mispricing Undervalued Controlled | |
| 2025 Q3 |
HealthcareHealthcare was the strongest relative contributor in the quarter with holdings increasing nearly +16% compared to benchmark returns of roughly +12%. Exact Sciences was acquired for a significant premium by Abbott Laboratories resulting in an +86% return, while other strong performers included Tarsus Pharmaceuticals, Glaukos following approval of a new product, Penumbra, and Repligen driven by strong earnings results. |
M&A Product Approval Earnings Biotech |
| 2025 Q2 |
ValueThe manager continues to find attractive value opportunities despite expensive markets, purchasing undervalued companies like Centene, GlaxoSmithKline, Carrefour and PayPal trading at low multiples with strong fundamentals. |
Undervalued Low Multiples Contrarian Opportunistic |
| Date | Pitch Type | Author | Ticker | Company | Industry | Sub Industry | Bull / Bear | Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 2, 2025 | Fund Letters | Andrew Summers | DERM | Journey Medical Corporation | Health Care | Specialty Pharmaceuticals | Bull | NASDAQ | dermatology, Druglaunch, FDA, growth, pharmaceuticals | Login |
| Jan 12, 2026 | Fund Letters | Andrew Summers | CCSI | Consensus Cloud Solutions Inc. | Information Technology | Application Software | Bull | NASDAQ | buybacks, deleveraging, Healthcareit, rerating, spin-off | Login |
| TICKER | COMMENTARY |
|---|---|
| CCSI | Entry Price: $16 USD. Valuation at Entry Price: 3.5x EPS. Change that Occurred: Management announced a new capital allocation policy to pay down debt (Q4 2023). New Clarity clinical documentation services launched (Q1 2024). Price Target: $58/share. 145% upside. |
| ELMD | Investment in Electromed (ELMD). Return of 108% net and IRR of 21.3% net. |
| NVO | added a new holding in Novo Nordisk, which had seen its share price decline by two thirds since mid-2024 |
| Ticker | Put/Call | Amount Bought | Shares Bought | % Change | Weight % |
|---|---|---|---|---|---|
| No Recent Buys Data | |||||
| Ticker | Put/Call | Amount Sold | Shares Sold | % Change | Weight % | Status |
|---|---|---|---|---|---|---|
| No Recent Sells Data | ||||||
| Industry | Prev Quarter % | Current Quarter % | Change |
|---|---|---|---|
| No industry data available | |||
